Nanologica AB (FRA:4YD) Cyclically Adjusted FCF per Share: €-0.03 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4YD Nanologica AB FRA:4YD
46 GF Score
Price €0.03
GF Value €0.04
Valuation Modestly Undervalued
! 9 Warning Signs
View Full Analysis

What is Nanologica AB Cyclically Adjusted FCF per Share?

Nanologica AB FRA:4YD -3.18% 46 Cyclically Adjusted FCF per Share is €-0.03 as of Mar. 2026. GuruFocus rates FRA:4YD with a GF Score™ of 46/100 and a GF Value™ of €0.04 (Modestly Undervalued). The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Nanologica AB's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.006. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.03 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-04), Nanologica AB's current stock price is €0.0304. Nanologica AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-0.03. Nanologica AB's Cyclically Adjusted Price-to-FCF of today is .


Nanologica AB  (FRA:4YD) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Nanologica AB Cyclically Adjusted FCF per Share Related Terms


Nanologica AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Nanologica AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanologica AB Cyclically Adjusted FCF per Share Chart

Nanologica AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.22 -0.15

Nanologica AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.24 -0.21 -0.19 -0.15 -0.03

FRA:4YD vs VRTX, REGN, RVMD: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Nanologica AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanologica AB Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanologica AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Nanologica AB's Cyclically Adjusted Price-to-FCF falls into.


FRA:4YD
46GF Score
Nanologica AB FRA:4YD
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanologica AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nanologica AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.006/133.5600*133.5600
=-0.006

Current CPI (Mar. 2026) = 133.5600.

Nanologica AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.147 101.019 -0.194
201609 -0.180 101.138 -0.238
201612 -0.146 102.022 -0.191
201703 -0.113 102.022 -0.148
201706 0.029 102.752 0.038
201709 -0.124 103.279 -0.160
201712 -0.266 103.793 -0.342
201803 -0.068 103.962 -0.087
201806 -0.023 104.875 -0.029
201809 -0.024 105.679 -0.030
201812 -0.005 105.912 -0.006
201903 -0.017 105.886 -0.021
201906 -0.031 106.742 -0.039
201909 0.006 107.214 0.007
201912 -0.012 107.766 -0.015
202003 -0.044 106.563 -0.055
202006 -0.075 107.498 -0.093
202009 -0.024 107.635 -0.030
202012 -0.049 108.296 -0.060
202103 -0.027 108.360 -0.033
202106 -0.049 108.928 -0.060
202109 -0.049 110.338 -0.059
202112 -0.053 112.486 -0.063
202203 -0.050 114.825 -0.058
202206 -0.042 118.384 -0.047
202209 -0.031 122.296 -0.034
202212 -0.036 126.365 -0.038
202303 -0.031 127.042 -0.033
202306 -0.043 129.407 -0.044
202309 -0.029 130.224 -0.030
202312 -0.029 131.912 -0.029
202403 -0.022 132.205 -0.022
202406 -0.046 132.716 -0.046
202409 -0.046 132.304 -0.046
202412 -0.029 132.987 -0.029
202503 -0.024 132.825 -0.024
202506 -0.001 133.699 -0.001
202509 -0.011 133.480 -0.011
202512 -0.010 133.390 -0.010
202603 -0.006 133.560 -0.006

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.03 mean?
Nanologica AB (FRA:4YD) has a Cyclically Adjusted FCF per Share of €-0.03 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Nanologica AB and its competitors.
Is Nanologica AB's Cyclically Adjusted FCF per Share too high?
Nanologica AB's current Cyclically Adjusted FCF per Share is €-0.03. Overall, Nanologica AB has a GF Score™ of 46/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nanologica AB's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Nanologica AB's Cyclically Adjusted FCF per Share of €-0.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Nanologica AB and its competitors. Nanologica AB's current Cyclically Adjusted FCF per Share is €-0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanologica AB stock overvalued right now?
Based on GuruFocus' analysis, Nanologica AB (FRA:4YD) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.04, compared to a current price of €0.03 — trading 24% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.03. Nanologica AB's overall GF Score™ is 46/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Nanologica AB (FRA:4YD), the current Cyclically Adjusted FCF per Share is €-0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nanologica AB (FRA:4YD) Overvalued in 2026?

Based on GuruFocus' analysis, Nanologica AB stock appears to be undervalued. The current stock price of €0.03 is trading 24% below its estimated GF Value™ of €0.04. GuruFocus considers Nanologica AB to be Modestly Undervalued.

Key valuation signals for FRA:4YD:

  • Cyclically Adjusted FCF per Share: €-0.03
  • GF Value™: €0.04 vs. price of €0.03 (24% below fair value)
  • GF Score™: 46/100 with 9 warning signs

No single metric tells the full story. See the FRA:4YD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nanologica AB Business Description

Other Exchanges NICA:Sweden
Address Forskargatan 20 G, Sodertalje, SWE, 151 36
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells key consumables to pharmaceutical manufacturers. Its products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, it can increase productivity and reduce costs for pharmaceutical manufacturers. The group operates in a world-wide niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
46GF Score

Get the complete analysis for FRA:4YD

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.03
Price
€0.04
GF Value